On repeat genomic profiling (TP53 p.W53*), potential sensitivities were suggested to buparlisib + paclitaxel (head and neck cancer), adavosertib, pazopanib + vorinostat (sarcoma), and GDC-0575 + gemcitabine (sarcoma). Here, TP53 is linked to head and neck cancer.